MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer.
about
Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and diseaseThe functional sites of miRNAs and lncRNAs in gastric carcinogenesismiRNA-133 augments coelomocyte phagocytosis in bacteria-challenged Apostichopus japonicus via targeting the TLR component of IRAK-1 in vitro and in vivo.A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma.Decreased miR-204 in H. pylori-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4.Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer.miR-183 inhibits invasion of gastric cancer by targeting Ezrin.microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemiaTumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis.MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4.MicroRNA-Specificity Protein (Sp) Transcription Factor Interactions and Significance in Carcinogenesis.Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancerIntegrated miRNA profiling and bioinformatics analyses reveal potential causative miRNAs in gastric adenocarcinomamiR-133b, a microRNA targeting S1PR1, suppresses nasopharyngeal carcinoma cell proliferation.Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer.Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladderPrognostic value of decreased microRNA-133a in solid cancers: a meta-analysis.miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer.ROR2 inhibits the proliferation of gastric carcinoma cells via activation of non-canonical Wnt signaling.MiRSEA: Discovering the pathways regulated by dysfunctional MicroRNAs.A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis.The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1.Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.The p53/microRNA connection in gastrointestinal cancer.Molecular functions and significance of the MTA family in hormone-independent cancer.MiR-133a-3p Inhibits Oral Squamous Cell Carcinoma (OSCC) Proliferation and Invasion by Suppressing COL1A1.Berberine upregulates miR-22-3p to suppress hepatocellular carcinoma cell proliferation by targeting Sp1.MicroRNA-149 targets specificity protein 1 to suppress human tongue squamous cell carcinoma cell proliferation and motility.A global burden of gastric cancer: the major impact of China.MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1.MicroRNAs contribution in tumor microenvironment of esophageal cancer.MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1.Inflammation and vascular smooth muscle cell dedifferentiation following carotid artery ligation.Prognostic value of candidate microRNAs in gastric cancer: A validation study.BDE-209 inhibits pluripotent genes expression and induces apoptosis in human embryonic stem cells.Combination of miRNA and RNA functions as potential biomarkers for gastric cancer.Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145.miR-133b, a particular member of myomiRs, coming into playing its unique pathological role in human cancer
P2860
Q26795757-70536293-33AC-4850-9776-9EE222F25E0CQ27026837-E1D09F10-B3E5-490E-AABC-B8FB1212D27CQ28646005-C5AA2A17-2F47-4281-A9B8-F6145259AA5FQ33798418-4257688D-5D8F-45C7-8F3E-CD2906E3E7D2Q33831182-3BF4C773-B91C-48B6-B74D-B58F20894528Q33846816-A5651384-995D-4EE7-9A49-53A988C4C5D3Q34371214-A8EC1DFD-9376-45EA-9AF5-BB92394D2AC3Q34504964-81CCEBD4-D538-4F39-9ED8-7888D2369C06Q35043364-1B833C7C-FA1E-4BB1-9351-F8E93CB306CDQ35169337-BA78D380-74D5-4054-A213-1CACB3BA0450Q35710429-552BB197-AC58-41A4-982D-C953151C1BF3Q36057179-C5DE8A53-0E18-4CC9-A9BC-54AAC03FDB0BQ36131780-6BA3DC73-286B-4DF7-B504-9547A3DAFCF3Q36278712-F662E761-F7CA-4C7C-B10B-2F5219F79B82Q36545009-D8BB8819-7A25-415C-948D-B3C031C44283Q36742085-E4FABB36-C8D3-4DA6-ACAB-524221B62F73Q36847230-289899C5-5EC1-481E-B040-45EBA9ADCEB4Q37148931-BDC1CB35-CCF4-4703-9BC3-245620EDA728Q37283359-256A1178-1AEC-4BB9-8B51-1E5C2B380C64Q37297592-5A8C7643-E04D-4571-8F3A-7348813C1869Q37581948-62B7583E-7BD0-4197-AB3E-D867841D9676Q37688181-C9674B08-50E0-4EDA-B1F2-4DE01B378CBCQ37701630-797F4A0A-03F1-4735-A508-9F0570AE86FBQ37706678-B8D43D9E-F42B-4252-9FAE-EBADDEDFA886Q38223512-A0EE123B-63E2-400F-B625-1970B5E7333FQ38261312-571FDE23-B11C-4CB6-AB6D-364DC0A10AC1Q38262308-4A4F1E48-7558-4F2D-861F-6D0650ADB0CCQ38701648-D3823F8C-B310-423D-9C88-8A462E4B96C4Q38728160-82FE5187-E4FD-46F6-8387-7165636B5752Q38737855-A9487B34-ED81-47D7-B704-1E71F769DF0BQ38738402-F514F80A-38B6-4725-9572-48B38B0E1E80Q38742757-2CFF36DE-E11D-4660-8769-FEAED880F1E7Q38793194-5C12332F-F6EB-4387-8A07-DB8876F11CC8Q38997887-D27492D3-92B1-4F98-A473-191531E68DF6Q39048502-BE5DE18E-6393-4384-AA8D-7E06182031AFQ40421691-87EA1CA8-528E-4332-8F01-8452646F3FA9Q40701300-3F724103-AD56-4C8D-A258-0A4014D4DE1DQ40743782-AE9EA740-06D6-4DDB-A08D-BB2A52773B0AQ41031640-04FCF519-D2B7-4432-8FE3-7576B9FCB3E5Q41473012-C35D2FEB-425E-420F-98FD-836C057860E8
P2860
MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
MiR-145, miR-133a and miR-133b ...... factor Sp1 in gastric cancer.
@en
MiR-145, miR-133a and miR-133b ...... factor Sp1 in gastric cancer.
@nl
type
label
MiR-145, miR-133a and miR-133b ...... factor Sp1 in gastric cancer.
@en
MiR-145, miR-133a and miR-133b ...... factor Sp1 in gastric cancer.
@nl
prefLabel
MiR-145, miR-133a and miR-133b ...... factor Sp1 in gastric cancer.
@en
MiR-145, miR-133a and miR-133b ...... factor Sp1 in gastric cancer.
@nl
P2093
P2860
P1433
P1476
MiR-145, miR-133a and miR-133b ...... factor Sp1 in gastric cancer.
@en
P2093
Tianzhu Qiu
Yongqian Shu
Zebo Huang
P2860
P304
P356
10.1016/J.FEBSLET.2014.02.054
P407
P577
2014-03-05T00:00:00Z